Pharmacist contributions to the ten essential services of public health in three National Association of Boards of Pharmacy regions

Global Scope of Hospital Pharmacy Practice: A Scoping Review

“…Similarly, nine studies reflected the clinical pharmacy services often offered in the majority of the hospitals [ 12 , 17 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ]. Two studies [ 28 , 29 ] focused on the engagement of hospital pharmacists’ in essential and nonessential public health services. Most of the studies, however, indicated a shift in practice toward nonpatient-oriented pharmacy services.…”

“…In Iowa and North Dakota [ 28 ], pharmacists generally played a role in disease state management, medication therapy management, care transition from inpatient to outpatient, prescription medication take-back, smoking cessation, and vaccination. Essential public health services—like the enforcement of health protection related laws and regulations, patient education on health-related issues, and participation in training outside the scope of continuing education requirements—were witnessed in Iowa, North Dakota, and Manitoba [ 29 ]. However, in Vietnam hospitals, pharmacists were not directly involved in health protection laws implementation [ 21 ].…”

The role of the pharmacist from development to pharmacovigilance of biosimilars

“…Pharmacist is the expert in all drugs and is also the most appropriate source of information about the use, therapeutic effect, adverse effect, mode of action, mode of administration, storage and dispensing of all drugs including biologics and biosimilars [24]. All drugs and drug products produced by conventional chemical synthesis or by ways of biotechnology or any other means remains the responsibility of the pharmacist [25][26]. The role of the pharmacist in the development of biosimilars is continuous starting from manufacturing to dispensing and post-marketing pharmacovigilance studies.…”

“…As they have close contact with patients, they should also be involved in the policy making and regulation processes. Besides education and counseling of stakeholders about the designing process, regulations and use of biosimilars are also among the responsibilities of the pharmacist [25][26][27].…”

“…While the innovative company may be fighting to maintain their market share and avoid competition, biosimilar advocates may be more interested in tapping from the fast growing biologic market. Pharmacists are in a position to maintain the balance between the two groups by observing this debate from the patients' perspective to provide quality products readily accessible and at affordable prices [22,[24][25][26].…”